Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mesalazine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine | DRUG | - |
| Mesalazine | DRUG | - |
Inclusion Criteria: * newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\> 1 and a PGA \<=2) with compatible histology * females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Mesalazine is used for the treatment of acute, mild to moderate ulcerative colitis, a form of inflammatory bowel disease affecting the colon and rectum. It is being developed as a small molecule therapy for this gastrointestinal condition.
Mesalazine is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda is listed on the stock exchange under the ticker symbol TAK.
Mesalazine is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its efficacy and safety in patients with ulcerative colitis.
Mesalazine has one completed Phase 3 clinical trial, identified as NCT00548574. This trial evaluated the efficacy and safety of two doses of Mesalazine, 2.4g and 4.8g once daily, compared with a reference treatment, in 343 subjects with acute, mild to moderate ulcerative colitis.
Mesalazine is a small molecule that works by delivering mesalazine, an anti-inflammatory agent, directly to the colon. It is designed to reduce inflammation in the gastrointestinal tract, which helps to alleviate the symptoms of ulcerative colitis.